In a major development for obesity treatment, the US Food and Drug Administration has approved the first oral version of Wegovy, marking a significant shift in how weight-loss medications can be administered. The approval was announced by Danish pharmaceutical giant Novo Nordisk, which described the tablet as the first FDA-cleared oral GLP-1 medication specifically approved for weight management in the United States.
Until now, Wegovy was available only as a once-weekly injection, a format that posed challenges for many patients who are uncomfortable with needles or struggle with long-term adherence. The newly approved pill is taken once daily and is expected to deliver weight-loss results comparable to the injectable version, potentially expanding access to treatment for millions of people living with obesity.
According to Novo Nordisk, clinical trials involving around 1,300 participants showed strong and consistent outcomes. People taking the Wegovy pill lost an average of 16.6 percent of their body weight over the course of the study. Notably, nearly one-third of participants achieved weight loss of 20 percent or more, results that closely mirror those seen with the injectable form of the drug.
Wegovy belongs to the GLP-1 class of medications, which work by suppressing appetite, slowing digestion, and helping users feel full for longer periods. While similar GLP-1 drugs such as Ozempic have been widely used and linked to weight loss, they were originally approved to treat Type 2 diabetes. Wegovy, in contrast, received FDA approval specifically for chronic weight management, making it distinct in its regulatory positioning.
Novo Nordisk announced that the oral Wegovy pill will be launched in the US market in early January 2026. Pricing details and insurance coverage information have not yet been disclosed, but healthcare experts stress that affordability will play a critical role in determining how widely the pill is adopted. If priced competitively, the tablet could significantly broaden the reach of effective obesity treatment.
The approval comes at a crucial time for Novo Nordisk, which is facing intense competition from rival pharmaceutical companies, including Eli Lilly, in the rapidly expanding weight-loss drug market. Investors responded positively to the news, with the company’s shares jumping nearly 10 percent in after-hours trading in New York.
Health professionals believe the pill version of Wegovy could transform obesity care, particularly for patients who avoid injectable treatments. With global obesity rates continuing to rise, the availability of an effective, FDA-approved oral weight-loss drug is being widely seen as a meaningful step forward in public health and medical innovation.
